Extracranial stereotactic radiotherapy in low and favourable intermediate risk prostate cancer

被引：0
|
作者：
Navarro Aznar, V. [1 ]
Mendez Villamon, A. [1 ]
Puertas Valino, M. D. M. [1 ]
Garcia Aguilera, C. [1 ]
Cerrolaza Pascual, M. [1 ]
Lanuza Pascual, A. [1 ]
Ponce Ortega, J. M. [1 ]
Colom, C. [1 ]
Garcia Gimeno, B. [1 ]
Tejedor Gutierrez, M. [1 ]
机构：
[1] Miguel Servet Hosp, Radiat Oncol, Zaragoza, Spain
来源：
RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1499
引用
收藏
页码：S1217 / S1218
页数：2
相关论文
共 50 条
  • [1] Ultrahypofractionated radiotherapy in low and favourable intermediate risk localised prostate cancer
    Colom Pla, Claudia
    Navarro Aznar, Victoria
    Garcia Aguilera, Cristina
    Cerrolaza Pascual, Maria
    Lanuza Carnicer, Alberto
    Galan Garcia, Ana
    Mendez Villamon, Agustina
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2530 - S2531
  • [2] Stereotactic ablative radiotherapy for low to intermediate risk prostate cancer
    Sadozye, A.
    Dodds, D.
    MacLeod, N.
    Lamb, C.
    Smith, S.
    Foster, J.
    Devlin, L.
    Dufton, A.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S679 - S680
  • [3] Stereotactic Body Radiotherapy for Localized Low-Intermediate Risk Prostate Cancer
    Haas, J.
    Santoro, M.
    Ashley, R.
    Mucciolo, R.
    Andrews, J.
    Clancey, O.
    Episcopia, K.
    Accordino, D.
    Sanchez, A.
    Witten, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S432 - S432
  • [4] Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    King, Christopher R.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (03) : 268 - 278
  • [5] Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?
    Helou, Joelle
    D'Alimonte, Laura
    Quon, Harvey
    Deabreu, Andrea
    Commisso, Kristina
    Cheung, Patrick
    Chu, William
    Mamedov, Alexandre
    Davidson, Melanie
    Ravi, Ananth
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 (03) : 478 - 482
  • [6] Radiotherapy in low and intermediate-risk prostate cancer
    Yalman, Deniz
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 86 - 91
  • [7] Stereotactic body radiotherapy for low and intermediate risk prostate cancer: Four-year outcomes.
    Potharaju, Mahadev
    Ravishankar, L. S.
    Sasikumar, Neetu
    Sadiq, A. L., I
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    Dang, Audrey
    Katz, Alan J.
    Mantz, Constantine A.
    Collins, Sean P.
    Aghdam, Nima
    Chu, Fang-I
    Kaplan, Irving D.
    Appelbaum, Limor
    Fuller, Donald B.
    Meier, Robert M.
    Loblaw, D. Andrew
    Cheung, Patrick
    Pham, Huong T.
    Shaverdian, Narek
    Jiang, Naomi
    Yuan, Ye
    Bagshaw, Hilary
    Prionas, Nicolas
    Buyyounouski, Mark K.
    Spratt, Daniel E.
    Linson, Patrick W.
    Hong, Robert L.
    Nickols, Nicholas G.
    Steinberg, Michael L.
    Kupelian, Patrick A.
    King, Christopher R.
    JAMA NETWORK OPEN, 2019, 2 (02)
  • [9] Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    RADIATION ONCOLOGY JOURNAL, 2016, 34 (04): : 260 - 264
  • [10] Prospective Evaluation of Stereotactic Radiotherapy for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dose Distribution
    Fuller, D. B.
    Mardirossian, G.
    Wong, D.
    McKellar, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S358 - S359
12345